Neurologists are not Immune to Diseases they Treat Daniel Gibbs, MD, PhD, is a neurologist and a scientist that has spent his career face-to-face with Alzheimer’s disease; studying tissue samples in a lab and treating patients at the Oregon Health & Science University in Portland. In his retirement, he pieced together clues that hinted at a diagnosis of the disease

Sticky Ideas Good ideas have a sticky quality; they hang around until they’re put into action. Bipartisan legislation that was recently reintroduced in the U.S. House of Representatives proves this. The Improving Seniors’ Timely Access to Care Act, H.R. 3173, again seeks to reform prior authorization processes of Medicare Advantage (MA) plans and require “real time” decisions in certain cases.

Fail First Doesn’t put Patients First Fail first policies require patients to use treatments preferred by their insurance company before treatment prescribed by their physicians. These policies have very serious impacts on patients, young and old. Practicing rheumatologist David Karp, MD and Ann M. Palmer, President & CEO of the Arthritis Foundation explain how patients pay a steep price at

Patients are the Best Teachers In her podcast, Anamnesis by MedPage, Amy Faith Ho, M.D. focuses on eureka, “that moment when things just ... click.” She credits special moments of physician-patient interaction for ‘eureka moments.’ She reflects “Patients are the best teachers. As much as we teach patients… they teach us so much more back.” In the podcast, three physicians

Progress toward Personalized Cancer Vaccine Vaccines are on the minds of people around the globe. The Journal of the American Medical Association (JAMA) recently provided an encouraging update on a different kind of vaccine under development – a cancer vaccine. JAMA reported that a “peptide vaccine personalized for individual patients with different cancer types” cleared a phase 1 clinical trial.

The Right Treatment at the Right Time does the Patient Right Policies to reduce the price of medication should not reduce access to it. Lowering what Americans pay for drugs is pointless if patients are denied access to therapies their physicians prescribe. Khrystal K. Davis, parent and caregiver of a child with a rare disease, patient advocate and founder of